Low Risk of Failing Direct-Acting Antivirals in People With Human Immunodeficiency Virus/Hepatitis C Virus From Sub-Saharan Africa or Southeastern Asia: A European Cross-Sectional Study.

Background

Several studies have reported suboptimal efficacy of direct-acting antivirals (DAAs) to treat hepatitis C virus (HCV) subtypes endemic to sub-Saharan Africa (SSA) and Southeastern Asia (SEA). The extent of this issue in individuals with human immunodeficiency virus (HIV)/HCV from SSA or SEA residing in Europe is unknown.

Methods

We retrospectively analyzed data from several prospective European cohorts of people living with HIV. We included individuals with HIV/HCV who originated from SSA or SEA, were treated with interferon-free DAAs, and had an available HCV RNA result ≥12 weeks after the end of treatment. The primary outcome was sustained virological response at least 12 weeks after the end of treatment (SVR

Results

Of the 3293 individuals with HIV/HCV treated with DAA and with available SVR

Conclusions

SVR

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America.

Déclaration de conflit d'intérêts

Potential conflicts of interest. C. I. has received research funding from Gilead, not related to this study. A. M. has received honoraria, travel support, and/or consultancy fees from ViiV, Gilead, and Eiland & Bonnin, all outside the submitted work. K. F. has received honoraria from GSK, AbbVie, and Gilead, all outside the submitted work. G. W. has received unrestricted research grants form Gilead Sciences and Roche Diagnostics, unrelated to this work, as well as honoraria from ViiV, MSD, and Gilead Sciences (paid to his institution). M. C.'s institution received a conference grant from Gilead as well as research grants from Gilead, MSD, and ViiV. M. S. has received grants for conference participation from Gilead and MSD (Merck). J. S.'s institution has received research support and consultancy fees from Gilead, and a speaker’s fee from Janssen Pharmaceuticals, independent from the submitted work. A. R. reports support to his institution for advisory boards and/or travel grants from MSD, Gilead Sciences, Pfizer, and AbbVie, and an investigator-initiated trial grant from Gilead Sciences. All remuneration went to his home institution and not to A. R. personally, and all remuneration was provided outside the submitted work. M. v. d. V. reports honoraria or research grants from AbbVie, Gilead, MSD, and ViiV Healthcare, all outside the submitted work. All other authors report no potential conflicts.